Scalable MCL1 Inhibitor Synthesis With Modular Intermediates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for synthetic methods and intermediates to prepare MCL1 inhibitors on a manufacturing scale, as existing methods are inadequate for large-scale production.
Innovation Solution
The methods involve synthesizing compounds of Formula A, comprising four functional regions: a tetracyclic core, a disubstituted cyclobutane moiety, a multi-substituted sulfonimidamide moiety, and an N-linked side-chain, with critical bonds formed in various orders to produce MCL1 inhibitors, using specific reagents, solvents, and conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing synthetic methods are used to prepare MCL1 inhibitors, then the compounds can be produced, but the methods are inadequate for large-scale manufacturing
Solution Approach 1:
The patent divides the synthesis into modular segments by defining four distinct functional regions (tetracyclic core, disubstituted cyclobutane moiety, multi-substituted sulfonimidamide moiety, and N-linked side-chain) that can be independently synthesized and then assembled. This segmentation allows each region to be optimized separately for scale-up while maintaining overall compound integrity, directly addressing the inadequate existing methods for large-scale production.
2Productivity
If compounds are synthesized with four distinct functional regions assembled in various orders, then manufacturing scalability is improved, but the synthesis process complexity increases
Solution Approach 1:
The patent establishes a universal synthetic framework where the four functional regions can be assembled in multiple sequences (various orders of bond formation) to produce the same final compound structure. This multi-functional approach allows the synthesis process to be adapted to different manufacturing constraints and scales while maintaining product consistency, balancing scalability with manageable process complexity.
Data Source
AI summary
The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.